Skip to content
Business
Prognosis

Pfizer Course May Have 23% Efficacy Vs. Omicron: Study

  • South African institute releases additional data on study
  • Immunity is still likely strong enough to curb severe disease
Germany to Enforce 'Lockdown for Unvaccinated' With Covid Surging
Photographer: Michaela Handrek-Rehle/Bloomberg
Updated on

A two-shot course of Pfizer Inc.’s vaccine may have just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa.

Researchers at the Africa Health Research Institute in Durban issued additional data on a small study released earlier this week from which they made an estimate of the efficacy of the vaccine using modeling.